Gilead Sciences Inc. entered into a global partnership with Galapagos NV in view of the further developing treatment of rheumatoid arthritis and other inflammatory diseases. Gilead Sciences Inc. invested USD 425 million equity in Galapagos and an additional USD 300 million in license fees. Arrangements on milestone and royalty payments have been set in place.
Eubelius assisted Gilead Sciences on the Belgian corporate aspect of the partnership, alongside Skadden Arps as global counsel. The Eubelius team was led by Marieke Wyckaert and Joris De Wolf.
Matter Type
JV/Alliance/Licence
Industry
Healthcare, Life Sciences & Chemicals
News Category
Corporate & Commercial